DexCom, Inc.
DexCom, Inc. (DXCM) designs and sells continuous glucose monitoring (CGM) systems used by people with diabetes and healthcare providers. Its product suite—sensors, transmitters and supporting software—aims to provide real‑time glucose readings and trend data, with recurring revenue from consumable sensors and subscription services. Key positives include strong adoption in type 1 diabetes, a growing addressable market among type 2 patients, ongoing product upgrades (including smaller form factors) and partnerships with insulin‑delivery firms. Risks include competitive pressure (from established medical device makers and newer entrants), reimbursement and regulatory outcomes across markets, supply chain constraints and the potential for device recalls or pricing pressure. With a market capitalisation around $27.4bn, DexCom is often viewed as a growth‑oriented medical device company; investors should weigh revenue visibility from consumables against execution and regulatory risks. This is general information only, not personalised investment advice; returns are not guaranteed and share values can fall as well as rise.
Why It's Moving
Dexcom Shines at ATTD 2026 with Breakthrough Type 2 Diabetes Data Fueling Analyst Optimism
- Showcased game-changing clinical outcomes for Type 2 diabetics, proving CGM efficacy beyond Type 1 and broadening market potential.
- Revealed ambitious product roadmap at ATTD, signaling innovation pipeline to drive future adoption and revenue growth.
- Appointed tech veteran Rick Osterloh to its board, bolstering strategic expertise amid competitive glucose monitoring landscape.
Dexcom Shines at ATTD 2026 with Breakthrough Type 2 Diabetes Data Fueling Analyst Optimism
- Showcased game-changing clinical outcomes for Type 2 diabetics, proving CGM efficacy beyond Type 1 and broadening market potential.
- Revealed ambitious product roadmap at ATTD, signaling innovation pipeline to drive future adoption and revenue growth.
- Appointed tech veteran Rick Osterloh to its board, bolstering strategic expertise amid competitive glucose monitoring landscape.
When is the next earnings date for DexCom, Inc. (DXCM)?
DexCom's next earnings date is estimated between April 23 and April 30, 2026, as the company has not yet announced an official date, with projections based on historical patterns following the Q4 2025 and full-year 2025 release on February 12, 2026. This report will cover Q1 2026 results. Investors should monitor for official confirmation in the coming weeks.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying DexCom's stock as it has a target price of $86.89, indicating growth potential.
Financial Health
DexCom is successfully generating strong revenue and cash flow, reflecting its solid market position.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring DXCM
At-Home Treatment Revolution | FDA Approval Impact
The FDA's approval of an injectable, at-home version of Eisai and Biogen's Alzheimer's drug signals a major shift in chronic disease management. This creates an investment opportunity in companies that develop advanced drug delivery systems and support at-home patient care.
Published: September 1, 2025
Explore BasketAt-Home Healthcare Stocks Explained | FDA Approval
The FDA's approval of an injectable, at-home version of Eisai and Biogen's Alzheimer's drug simplifies treatment and reduces the need for hospital visits. This development highlights a broader trend toward at-home care, creating potential investment opportunities in companies that provide related medical devices and healthcare services.
Published: August 30, 2025
Explore BasketWearable Tech IP Wars: What Investors Should Know
Masimo's lawsuit against U.S. Customs, following a reversal of an import ban on Apple Watches, highlights the fierce competition over intellectual property in wearable health. This theme focuses on the medical technology companies and competitors poised to benefit from the ongoing patent battles in the lucrative health-monitoring device market.
Published: August 21, 2025
Explore BasketPharma's Digital Prescription
Novo Nordisk is partnering with GoodRx to offer its popular drug Ozempic at a reduced price, boosting GoodRx's stock. This collaboration highlights a growing trend of pharmaceutical companies leveraging digital health platforms to improve drug affordability and expand market reach.
Published: August 19, 2025
Explore BasketDigital Therapeutics & Prescription Apps
Software is becoming the new medicine. These carefully selected companies are developing FDA-cleared applications that treat everything from mental health to diabetes. With growing insurance reimbursement and massive scalability, these digital treatments represent healthcare's next frontier.
Published: June 17, 2025
Explore BasketDigital Therapeutics
Software that works like medicine. These companies are creating clinically validated digital tools that treat and manage diseases just like traditional pharmaceuticals, but with the scalability of technology. Professional investors see enormous potential in this rapidly evolving healthcare frontier.
Published: June 17, 2025
Explore BasketBio-Hacking Portfolio
Discover companies at the cutting edge of human optimization, where biology meets technology. These carefully selected stocks represent innovators developing data-driven solutions for personalized health, enhanced performance, and extended longevity.
Published: June 17, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Recurring revenue growth
Consumable sensors and subscription services support revenue predictability, though sales can fluctuate with reimbursement and competitive dynamics.
Product innovation pipeline
Smaller sensors, improved accuracy and system integrations keep the product roadmap active, but technical or regulatory setbacks can affect adoption.
Global expansion potential
International markets present sizeable opportunity as CGM adoption rises, balanced by differing regulatory regimes and payer systems that can slow rollout.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
Abbott Laboratories
Abbott Laboratories is a global healthcare company that develops and markets a broad range of health care products, including medical devices, diagnostics, nutritionals, and branded generic pharmaceuticals.
Agilent Technologies Inc.
Agilent Technologies, Inc. specializes in life sciences, diagnostics and applied markets, providing application-focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. Its segments include Life Sciences and Diagnostics Markets, Agilent CrossLab and Applied Markets. The Life Sciences and Diagnostics Markets segment provides contract development and manufacturing services for pharmaceutical customers as well as solutions that include reagents, instruments, software and consumables which enable customers in the clinical and life sciences research areas to interrogate samples at the cellular and molecular level. The Agilent CrossLab segment spans the entire lab with its services and consumables portfolio in addition to software and laboratory automation solutions, which are designed to improve customer outcomes and represent a range of offerings designed to serve customer needs across end-markets and applications.
Align Technology Inc.
Align Technology is a medical device company that designs, manufactures and markets a range of dental and orthodontic products.
